PDS Biotechnology Stock Forum

$PDS Biotechnology(PDSB.US)$
swing target of 6.5

$PDS Biotechnology(PDSB.US)$
PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the first quarter of 2024 and provide a business update on Wednesday, May 15, 2024, before the...

$PDS Biotechnology(PDSB.US)$
NEWS
PDS Biotechnology Announces Details of Virtual KOL Event
PDS Biotechnology announced details of a virtual Key Opinion Leader (KOL) event focusing on updated Phase 2 trial results and unmet needs in advanced head and neck cancer. The event will discuss the positive data from the VERSATILE-002 trial and plans for a triple combination trial. Panel participants include renowned experts in the field.
Positive data from the VERSATILE-002 Phase 2 clinical trial
Focus o...

$SPDR S&P Biotech ETF(XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

$PDS Biotechnology(PDSB.US)$ nice uptrend for a while here looks interesting!

$PDS Biotechnology(PDSB.US)$ 👀

$PDS Biotechnology(PDSB.US)$$PDSB $PDSB JUST ANNOUNCED 75% CANCER SURVIVAL RATE KABOOM STAMP 11/9/23 721AM

$PDS Biotechnology(PDSB.US)$ Mayank Mamtani’s Buy rating for PDS Biotechnology Corporation is based on a number of significant factors. He highlighted the promising initial immunogenicity data from the ongoing VERSATILE-002 trial of PDS0101 + Keytruda for treating HPV16-positive head & neck squamous cell carcinoma. These findings were supportive of previously impressive results including 27% confirmed overall response rate, median progression-free survival of 8.1 months and an 80% one-year...